CORRELATION BETWEEN AREAS OF HIGH FDG UPTAKE ON PRE-TREATMENT PET/CT AND PREFERENTIAL SITES OF LOCAL RELAPSE AFTER CHEMO-RADIOTHERAPY FOR HEAD AND NECK.

Slides:



Advertisements
Similar presentations
Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD
Advertisements

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Overskrift her Navn på oplægsholder Navn på KU- enhed For at ændre ”Enhedens navn” og ”Sted og dato”: Klik i menulinjen, vælg ”Indsæt” > ”Sidehoved / Sidefod”.
H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.
18F- FDG PET/CT in the Diagnosis of Tumor Thrombosis
V. Budach – Statements on H&N Cancer - 1 Discussion Panel on Primary Radiochemotherapy Volker Budach, MD, PhD Head Department for Radiation Oncology Charité.
Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.
ISSSMA June 3 rd Advanced quantification in oncology PET Irène Buvat IMNC – UMR 8165 CNRS – Paris 11 University Orsay, France
Comparison of MRI Perfusion and PET-CT in Differentiating Brain Tumor Progression from Radiation Injury after Cranial Irradiation T. Jonathan Yang, M.D.
Update on 18 F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/ Computed Tomography Imaging of Squamous Head and Neck.
M. Wissmeyer Department of Nuclear Medicine, University of Berne (Inselspital) PET/CT in Radiation Oncology: Current Evidence and Future Perspectives.
Results of an Ontario Clinical Oncology Group (OCOG) prospective cohort study on the use of FDG PET/CT to predict the need for.
A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
Functional Imaging with PET for Sarcoma Rodney Hicks, MD, FRACP Director, Centre for Molecular Imaging Guy Toner, MD, FRACP Director, Medical Oncology.
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
RTOG1106: Randomized Phase IIR Trial of Personalized Adaptive Radiotherapy Based on Mid-treatment FDG-PET in Locally Advanced NSCLC P.I.: Feng-Ming (Spring)
Definitive radiotherapy for head and neck cancer: the use of physical exam versus computed tomography to manage the post-RT neck Stanley Liauw*, Robert.
Albert J. Chang, MD, PhD 1 Farrokh Dehdashti, MD 2 Perry W. Grigsby, MD, MS 1 Department of Radiation Oncology 1 Department of Radiology and Nuclear Medicine.
Monday Case of the Day A) The treatment was successful: The bremsstrahlung SPECT (Fig 2) indicates that 90 Y was deposited in the tumor. B) The treatment.
Univariate Analyses Treatment Outcome And Patterns Of Relapse Following Adjuvant Carboplatin For Stage I Testicular Seminoma: Results From a 17 Year UK.
Beth Israel plugin : A new free software tool for metabolic tumor volume calculation on PET/CT Objective: Salim Kanoun 1,2, Ilan Tal 3, Alina Berriolo-Reidinger.
JESÚS SILVA-RODRÍGUEZ, PABLO AGUIAR, INÉS DOMÍNGUEZ-PRADO, MICHEL HERRANZ, ÁLVARO RUIBAL 18F-Choline: Is shine-through effect an issue for prostate SUV.
OPTIMAL STRATEGY FOR PROPHYLACTIC CRANIAL IRRADIATION IN LIMITED STAGE SMALL CELL LUNG CANCER Patricia Tai 1, Avi Assouline 2,3, Kurian Joseph 4, Edward.
간담도 암에서의 PET 의 활용 핵의학과 홍일기. 18 F-FDG PET: Warburg effect.
Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a complex growth pattern. Imaging plays a crucial role in diagnosis.
DEPT OF RADIATION ONCOLOGY Prognostic Value of Post-Radiotherapy FDG PET in Head and Neck Cancer after Intensity Modulated Radiation Treatment Heming Lu.
BENEFIT OF CONSOLIDATIVE RADIATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP CHEMOTHERAPY JACK PHAN, ALI MAZLOOM, L. JEFFREY.
A prospective study of PET/CT in initial staging of small-cell lung cancer : comparison with CT, bone scintigraphy and bone marrow analysis B. M. Fischer1,
Fig. 9. Warthin's tumor, a 72-year-old man with supraglottic cancer. A
Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer  Nadya Shusharina, PhD,
Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer  Julie Leseur, Geoffrey Roman-Jimenez, Anne Devillers,
Volume 75, Issue 1, Pages (January 2012)
Pre-operative hyperfractionated radiotherapy and concurrent 5-fu/cisplatin for locally advanced esophageal cancer - the impact of 18-F-fluoro-deoxy-d-glucose.
Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer  Shervin M. Shirvani, MD, Ann.
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Thursday Case of the Day
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Image fusion between 18F-FDG-PET and MRI in cardiac.
Feasibility of hippocampal sparing radiation therapy for glioblastoma using helical Tomotherapy Dr Kamalram THIPPU JAYAPRAKASH1,2,3, Dr Raj JENA1,4 and.
Simultaneous positron emission tomography (PET) assessment of metabolism with 18F- fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F-fluoro-thymidine.
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Integration of Positron Emission Mammography (PEM)
Fig. 10. MIP (A, C) and axial non contrast fused 18F-FDG PET/CT (B) in 20-year-old man with ALK positive anaplastic large cell lymphoma. A. Patient had.
Whole Body 18F-FDG PET/CT Imaging Staging of Malignant Melanoma:
Relationship between the site of esophageal carcinoma and survival of patients with locally advanced disease Authors: Andrea Masarykova, Ingrid Zavacka,
Prognostic value of 18F-FDG PET/CT in patients with oropharyngeal squamous cell carcinoma Leo Jia, BA1, Joyce Hsu, BS1, Eran Rotem, MD, MPH2, Hadyn Williams,
CT-based surrogates of pulmonary ventilation in lung cancer:
Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer  Shervin M. Shirvani, MD, Ann.
Snail Enhances Glycolysis in the Epithelial-Mesenchymal Transition Process by Targeting FBP1 in Gastric Cancer Cell Physiol Biochem 2017;43:31–38 - DOI: /
A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial.
The Comparison of Computed Tomography Perfusion, Contrast-Enhanced Computed Tomography and Positron-Emission Tomography/Computed Tomography for the Detection.
Volume 65, Issue 4, Pages (April 2014)
Avinash Kambadakone Ramesh1
Future of Thoracic PET Scanning
18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.
Integrated positron emission tomography (PET)/computed tomography (CT)
Incidental finding of a nodular lesion in the right upper lobe
Future of Thoracic PET Scanning
Glucose Metabolism in NSCLC Is Histology-Specific and Diverges the Prognostic Potential of 18FDG-PET for Adenocarcinoma and Squamous Cell Carcinoma  Olga.
When is it Best to Repeat a 2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer.
Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality.
The impact of 18F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: Results from Westmead Hospital, Sydney, Australia  Rebecca.
Metabolic response by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). a) FDG PET/CT for patient 2 at baseline.
A, b, e, f) Computed tomography (CT) of the chest and c, d) positron emission tomography (PET) with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (18F-FDG)
Representative CT and PET/CT images of three patients with NSCLCs
Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.
Computer-aided Quantification of Pulmonary Fibrosis in Patients with Lung Cancer: Relationship to Disease-free Survival Of 217 patients with lung cancer,
Representative CT and PET/CT images of three patients with NSCLCs
Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &
Fig. 1.Representative images of 18F-FDG PET-CT and immunohistochemical staining for TILs. (A) Whole-body 18F-FDG PET image demonstrates increased FDG uptake.
Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT  Shuichi.
Presentation transcript:

CORRELATION BETWEEN AREAS OF HIGH FDG UPTAKE ON PRE-TREATMENT PET/CT AND PREFERENTIAL SITES OF LOCAL RELAPSE AFTER CHEMO-RADIOTHERAPY FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA. A. Chaput*1, J. Calais*2,3, P. Robin1-4, S.Thureau3, D. Bourhis1, R. Modzelewski3, U. Schick5, P. Vera3, P-Y. Salaün1-4, R. Abgral1-4. These two authors contributed equally to this work 1- Department of Nuclear Medicine, Brest University Hospital, Brest, France 2- Department of Nuclear Medicine, Bichat University Hospital, Inserm 1148, DHU FIRE, Assistance Publique - Hôpitaux de Paris, Paris, France 3- Department of Nuclear Medicine and Radiology, Henri Becquerel Center, QuantIF (LITIS EA 4108 – FR CNRS 3638), Rouen University Hospital, Rouen, France. 4- European University of Brittany, EA3878 GETBO, IFR 148, Brest, France 5- Department of Radiotherapy, Brest University Hospital, Brest, France. . PURPOSE The potential benefits of 18F-Fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET/CT) imaging for radiotherapy (RT) planning treatment of head and neck squamous cell carcinoma cancer (HNSCC) are increasingly being recognized. It has been suggested that intra-tumor sub-volumes with high FDG avidity (“hotspots”) are potential target for selected dose escalation [1-2]. Our aims were to demonstrate that pre-RT FDG PET/CT can identify intra-tumor sites at increased risk of local relapse (LR) after RT and to determine an optimal maximum standardized uptake value (SUVmax) threshold to delineate smaller RT target volumes that would facilitate RT dose escalation without impaired tolerance. METHODS The study included 72 consecutive patients with locally advanced HNC treated by radiotherapy ± concurrent chemotherapy. All patients underwent FDG PET/CT at initial staging (PETA) and during systematic follow-up (PETR) in a single institution. FDG PET/CT acquisitions were co-registered on the initial CT scan with a rigid method. Various sub-volumes (AX; X=30, 40, 50, 60, 70, 80 and 90% SUVmax thresholds) within the initial tumor and in the subsequent LR (RX; X=40 and 70% SUVmax thresholds) were pasted on the initial PET/CT and compared together [Dice, Jaccard, overlap fraction (OF), common volume/baseline volume, common volume/recurrent volume] (Fig.1) Fig. 2 : Patterns of relapses Fig. 1 Typical A70 R40 sub-volumes overlapping estimation after co-registration and reports. Numbers indicate the SUVmax thresholds in percentage. RESULTS Nineteen patients (26%) had LR (Fig.2). Using a 40% of SUVmax threshold, initial metabolic tumor volume (MTV) was significantly higher in all relapse patients (local and distant relapse) than in controlled patients (mean: 11.3±9.8 vs. 5.1±4.9 cc, p=0.001) as well as total lesion glycolysis (TLG) (mean: 134.6±116 vs. 60.6±80.4, p=0.002). For both using methods, the overlap index between A30, A40, and A50 sub-volumes on PETA and the whole metabolic volume of recurrence R40 and R70, on PETR showed a moderate agreement (between 0.40 and 0.60) (Fig.3). Example 1: 45-year-old woman with an oropharynx squamous cell carcinoma T4N2bM0. The A50 sub-volume was reported on PETR and the R40 and R70 sub-volumes on PETA. The A50∩R40 OF index was calculated at 0.53, meaning that half of R40 was included in A50. The A50∩R70 OF index was calculated at 0.77 meaning that three quarters of R70 was included in A50. Example 2: 49-year-old woman with a T4N2cM0 carcinoma. The overlap index were calculated all inferior to 0.4. But we can visually see the obvious mis-registration due to tumor decreasing and glottic position. High 18F-FDG uptake sub-volume of initial tumor (i.e. A70) is on the same side that the core of the residual tumor (i.e. R70) and close from it. We can suppose that with an accurate co-registration, overlap index would have been much higher. Fig. 3: Histogram of the mean values of overlap indices for various SUVmax thresholds to delineate the volumes on PETA (baseline, AX) and PETR at relapse, (R40 and R90). See the text for a description of the indices. The data are the same as those in Tables 4 and 5. CONCLUSIONS We confirm that TLG and MTV are independently correlated with recurrence-free survival in patients with HNSCC [3-4]. . Due to sub-optimal co-registration, we could not reach high overlap index values between initial tumor and recurrence sub-volumes. Further larger prospective studies with FDG-PET/CT performed in the same RT position and with a validated elastic registration method are needed. 1. Calais et al. J Nucl Med 2015;56:196-203. 2. Calais et al. Eur J Nucl Med Mol Imaging 2015;42:858-67. 3. Abgral et al. Eur J Nucl Med Mol Imaging 2014;41:659-67 4. Abgral et al. Head Neck 2016;38:600-8 P2707